C Ray Therapeutics Positions China-Based IIT Model as Accelerator for Radiopharmaceutical Development

According to a recent LinkedIn post from C Ray Therapeutics, industry interest in China’s Investigator-Initiated Trial, or IIT, model is rising, particularly around radiopharmaceutical development. The post notes that discussions at the JPM Healthcare Conference and an FDA cell and gene therapy roundtable referenced IIT as a potential dual-track approach for accelerating early human validation.

The company’s LinkedIn post highlights three drivers for this attention: translational uncertainty between animal and human biodistribution, complex dose selection in radioligand therapies, and investor demand for earlier de-risking signals via human data. As shared in the post, these factors appear to position IIT as a tool to generate early clinical insights before committing to larger, costlier trials.

According to the post, C Ray Therapeutics reports experience with applying this model to next-generation radiopharmaceuticals, citing timelines of six to nine months from formulation to first-in-human studies, more than 150 enrolled subjects, and over 10 IIT sites across China. If scalable and compliant with evolving global regulatory expectations, such capabilities could reduce capital at risk in early programs and potentially make the company a more attractive partner for global drug developers.

The post also points to upcoming industry visibility for the company, with its Sr. Director of Business Development scheduled to speak at the TRP Target Selection & Drug Design Summit in Boston in February 2026 on preclinical strategies to ease Phase Zero or first-in-human trials. For investors, increased thought-leadership exposure around IIT and radiopharmaceutical innovation may signal a strategy focused on platform-like clinical execution advantages, which could influence future partnering, licensing, or fundraising opportunities in the radiopharmaceutical sector.